While early diagnosis and strict dietary control are vital for managing phenylketonuria, recent developments in drug therapies and personalised strategies aim to overcome long-standing challenges in achieving optimal metabolic control throughout life.
Phenylketonuria, or PKU, remains a lifelong metabolic disorder that demands early diagnosis, strict dietary control and careful monitoring, yet specialists say those measures do not always deliver ideal results over time. The condition prevents the body from properly breaking down phenylalanine, an amino acid found in protein-rich foods. Without treatment, the substance builds up in the blood and can cause serious neurological harm.
According to the Cleveland Clinic and the US National Institute of Child Health and Human Development, treatment centres on a low-phenylalanine diet started as early as possible after birth and maintained throughout life. That typically means avoiding high-protein foods and using special medical formulas or supplements to provide protein, vitamins, minerals and tyrosine, an amino acid that people with PKU may not make in sufficient amounts. Frequent blood testing is also needed to keep phenylalanine levels within target ranges.
Even so, adherence is a persistent challenge. The Paraguayan outlet Popular reported that adolescence and adulthood are often the hardest stages, when social pressures, cost and the demands of daily life can make the diet difficult to sustain. Laura Morel, a specialist with the PKU unit at Hospital General Pediátrico “Niños de Acosta Ñu”, said families still face obstacles in maintaining metabolic control and adequate nutrition across all stages of life.
That concern is reflected in medical literature, which has increasingly emphasised the need for individualised care and ongoing assessment of growth and development. A systematic review cited by Popular suggests that some children with PKU may show differences in growth during childhood and adolescence, even when treatment begins early. At the same time, newer drug approaches and therapies aimed at boosting residual phenylalanine hydroxylase activity are being studied as a way to raise natural protein tolerance and make the condition less restrictive for selected patients. For clinicians, the main message remains the same: PKU can be managed, but it still requires a long-term, personalised strategy that goes beyond diet alone.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
